Dr. Marc Rothenberg is the Founder and Director of the Cincinnati Center for Eosinophilic Disorders (CCED), an international referral center and leader in the research, treatment and use of novel approaches in eosinophilic disorders, has made fundamental contributions in elucidating and treating these disorders.

The CCED was the first center dedicated to eosinophilic disorders and now serves as a global leader and role model for understanding, elucidating, and treating eosinophilic gastrointestinal disorders (EGIDs). The CCED researchers under Dr. Rothenberg’s direction conduct leading basic, translational, and clinical studies to determine the causes of eosinophilic disorders, develop better treatments, and find a cure. The CCED has substantially contributed to the understanding of the clinical, epidemiologic, genetic, and pathogenetic etiology of EGIDs. Investigator-initiated studies have fueled the development of novel therapeutics and served as the primary site for multi-center drug trials.

Dr. Rothenberg is also the founding Director and Principal Investigator of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), which is part of the Rare Disease Clinical Research Network (RDCRN) of the NIH. CEGIR involves 12 sites in the USA and partners with patient advocacy groups. CEGIR conducts innovative clinical trials, trains scholars through a mentoring program, and orchestrated pilot studies.

Select Related Publications